### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Helge H. RASMUSSEN, et al.

Serial No.:

10/594,160

Group No.

1613

Filed: May 24, 2007

Examiner:

S. Townsley

For:

METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL

**CONDITIONS** 

Attorney Docket No.: U 016502-0

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT**

We draw the attention of the Examiner to the attached references (first page only for U.S. patent publications) which are also listed on the attached Form PTO-1449.

Respectfully submitted

c/o Ladas & Parry LLP 1040 Avenue of the Americas

New York, New York 10018-3738

Reg. No. 31053

Tel. No. (212) 708-1915

# CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

|       |   | IAILING             |   |
|-------|---|---------------------|---|
|       | deposited with the United States Postal Service in Box 1450, Alexandria, VA 22313-1450. | in an envelope addr | essed to the Commissioner for Patents, P. O.                          |
|       | 37 C.F.R. 1.8(a)  |                     | 37 C.F.R. 1.10*   |
|       | with sufficient postage as first class mail.  | × 🗖                 | as "Express Mail Post Office to Address"  Mailing Label No (mandatory |
|       | TRANSMISSION  |                     | EFS-WEB   |
|       | transmitted by facsimile to the Patent and Trademark Office. to (571)-273-8300          |                     | transmitted electronically  |
| Date: | October 27, 2011  | Signatu<br>John I   | re<br>Richards  |

(type or print name of person certifying)

| FORM PTO-1449   | ORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND |                | ATTY, DOCKET N   | IO. SERIAL NO     |  |
|---|---|----------------|--|-------------------|--|
| 7 01(10) 1-1-0  |   |                | U 016502-0   | 10/594,160        |  |
|   | TRADEMARK OFFICE                                    |                | Α  | APPLICANT         |  |
| INFORMAT  | TON DISCLOSURE                                      |                | Helge A. RASMUSSEN, et al.   |                   |  |
| STATEMENT BY APPLICANT  (Use several sheets if necessary) |   |                | FILING DATE  | GROUP<br>1613     |  |
|   |   |                | May 24, 2007   |                   |  |
|   | U.  | S. PATENT      | DOCUMENTS  |                   |  |
| Patent  | or Application                                      |                | Name   | Date              |  |
| a   |   |                | stic effect of a sulfonylurea<br>on-sulfonylurea Kchannel<br>and a phosphodiesterase 3<br>bitor              | 31 January 2002   |  |
|   |   |                | stic effect of a sulfonylurea<br>on-sulfonylurea Kchannel<br>and a phosphodiesterase 3<br>bitor              | 20 Novemer 2003   |  |
| 5,977,154   |   | Selective      | e beta 3 adrenergic agonist  | 2 November 1999   |  |
|   | FORI  | EIGN PATE      | NT DOCUMENTS   |                   |  |
|   | it or Application<br>lumber/Kind Code               |                | Name   | Date              |  |
| EP  | 0 236 624   | amine<br>prepa | tituted phenyl ethanol<br>es, processes for their<br>tration and pharmaceutical<br>ositions containing them. | 16 September 1987 |  |
| EP  | 0 678 511   | deriva         | olidine and oxazolidine atives, their preparation neir medical use.  | 25 October 1995   |  |

**FORM PTO-1449** 

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessary)

| ATTY, DOCKET NO.  | SERIAL NO.     |  |
|-------------------|----------------|--|
| <br>U 016502-0    | 10/594,160     |  |
| <br>APPLI         | CANT           |  |
| <br>Helge A. RASI | MUSSEN, et al. |  |
| <br>FILING DATE   | GROUP          |  |
| May 24, 2007      | 1613           |  |

### **NON-PATENT DOCUMENTS**

#### Articles

\*Hoang H. et al., "beta3-Adrenergic receptor activation decreases peripheral vascular resistance in heart failure by restoring endothelial dependant vasorelaxation via endothelial nitric oxide synthase upregulation", Journal of the American College of Cardiology, March, 3, 2004, Vol. 43 no. 5, p. 220A, No. 1144-133 (Abstract only)

\* Takahiro Horinouchi, et al., "B3-Adrenoceptor-mediated relaxation of guinea-pig gastric fundus smooth muscle: cAMP-independent characteristics and a primary role of 4-aminopyridine-sensiive voltage-dependent K+ (Kv) channels", Folia Pharmacol. Jpn, Suppl 1, 109P-111P (2002) — (Full Japanese version, English abstract only)

Horinouchi T and Koike K., "Functional identification of beta3-adrenoceptors in the guinea-pig ileum using the non-selective beta-adrenoceptor antagonist (+/-)-bupranolol.,", J Auton Pharmacol., August 2000, Vol. 20, No. 4, pp. 253-258

The Merck Manual, Japanese Version, December 10, 1999, 17th edition, pp. 1687-1707 (English version attached)

Ridley JM et al., Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine, J Physiol., June 15, 2003, Vol. 549, No. 3, pp. 667-672

London B et al., Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I (K, slow) and resistance to drug-induced qt prolongation., Circ Res., May 11, 2001, Vol. 88, No. 9, pp. 940-946

Lohse M. J. et al., "What is the role of β-Adrenergic Signaling in Heart Failure?" Circulation Research 14 Nov 2003 United States vol. 93, no. 10, 14 November 2003 (2003-11-14), pages 896-906, XP002458610, ISSN: 0009-7330

Cheng Heng-Jie et al: "Functional significance of β3-adrenergic receptor activation in heart failure", Journal of Molecular and Cellular Cardiology, vol. 33, no. 6, June 2001 (2001-06), page A20, XP002458611 & XVII Ishr World Congress of the International Society for Heart Research; Winnipeg, Canada; July 06-11, 2001 ISSN: 0022-2828

\* Irmer, M. et al: "Treatment of severe congestive heart failure with the beta-agonist fenoterol", Klinische Wochenschrift, vol. 59, no. 12, 1981, pages 639-645, XP000924969 – (English abstract only)

Sawa et al: "Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists" Current Medicinal Chemistry 2006, pp. 25-37

Rozec and Gauthier: "β3-Adrenoceptors in the cardiovascular system: Putative roles in human pathologies", Pharmacology & Therapeutics 111 (2006) 652-673

Brixius K., et al, "ENOS is not activated by nebivolol in human failing myocardium", Science Direct – Life Sciences 79 (2006) 1234-1241.

White C.N., et al, "Activation of camp-dependent signaling induces oxidative modification of the cardiac Na<sup>+</sup>-K<sup>+</sup> pump and inhibits its activity" J Biol Chem. (2010); 285(18):13712-20.

SERIAL NO. ATTY. DOCKET NO. FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND 10/594,160 U 016502-0 TRADEMARK OFFICE APPLICANT INFORMATION DISCLOSURE Helge A. RASMUSSEN, et al FILING DATE **GROUP** STATEMENT BY APPLICANT May 24, 2007 1613 (Use several sheets if necessary) Articles Fisher M.H., et al, "A Selective Human β<sub>3</sub> Adrenergic Receptor Agonist Increases Matabolic Rate in Rhesus Monkeys", J. Clin. Invest. Volume 101, Number 11, pp 2387-2393 (1998) Larsen T.M., et al, "Effect of a 28-d treatment with L-796568, a novel β<sub>3-</sub>adrenergic receptor agonist, on energy expenditure and body composition in obese men<sup>1-3</sup>", Am J Clin Nutr (2002), pp 780-788 Van Baak M.A., et al, "Acute effect of L-796568, a novel β<sub>3</sub>-adrenergic receptor agonist, on energy expenditure in obese men", Clinical Pharmacology and Therapeutics (2002), pp 272-279 Sarsero D., et al, "Validity of (-)-[3H]-CGP 12177A as a radioligand for the 'putative beta4-adrenoceptor' in rat atrium", Br J Pharmacol (1998(; 123(3): 371-80 - (Abstract only) Paul A., et al, "Gastroprotective effects of β<sub>3</sub>-adrenoceptor agonists on water immersion plus restraint streeinduced gastric ulcer in rats", Indian J Pharmacol Vol 36 issue 3 (2004), pp. 151-54 Naylor E.M., et al, "3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists", Bioorg Med Chem Lett 1998 Nov 3; 8(21): 3087-92 - (Abstract only) Kato H., et al, (2001) "Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Av/Ta diabetic obese mouse model". Diabetes: 50(1): pp 113-22 Roberts S.J., et al. (1999) "Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-beta2- and beta3-adrenoceptors in rat ileum" Br J Pharmacol 127(4):949-61 Harada H., et al. (2003) "Novel and Potent Human and Rat β<sub>3</sub>-adrenergic receptor agonists containing substituted 3-Indolylalkylamines", Bioorganic & Medicinal Chemistry Letters 13, pp 1301-1305 Huang Y., et al. (2004) "Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional. Energetic, structural, and cellular responses", Am J Physio Heart Circ Physiol; 286 (6): H2141-50 - (Abstract only) Barouch L.A., et al (2004) "6-3 Adrenergic Signaling is impaired in the ob/ob Mouse Model of Obesity", Abstracts from Scientific sessions 2004 - 962 William M., et al (2005) "The nitric oxide donor, sodium nitroprusside, stimulates the Na<sup>+</sup>-K<sup>+</sup> pump in isolated rabbit cardiac myocytes", The Journal of Physiology. English translation of conclusion of Nitani, H. et al., "Studies of plasma level and hemodynamics of Nadolol, a new  $\beta$  adrenergic blocking agent" (June 1984), Vol. 12, No. 6)